Skip to content

American Well AMWL Equity Method Investments

Equity Method Investments at other companies

DocGo logo
DocGoDCGO
$0-100%
Humana logo
HumanaHUM
$633M-3.9%
Evolent Health, Inc. logo
Evolent Health, Inc.EVH
$8.96M+4.5%
Astrana Health logo
Astrana HealthASTH
$27.26M-28.3%

Other financials

Income statement

See full
Revenue$54.9M-17.9%
Gross profit$28.0M-20.7%
Operating income-$17.4M+42.7%
Net income-$10.9M+41.8%
EPS (diluted)-$0.66+44.5%

Balance sheet

See full
Cash & equivalents$179.2M-19.4%
Total debt$4.0M-45.7%
Total equity$227.3M-22.7%
Total assets$326.0M-22.3%

Cash flow

See full
Operating cash flow-$983.0K+96.1%
CapEx$5.0K-44.4%
Free cash flow-$988.0K+96.1%

Valuation

See full
Market cap$154.55M+29.3%
Enterprise value-$20.69M-77.8%
P/S0.7×+0.2×

Profitability

See full
Gross margin52.9%+8.6pp
Operating margin-38.9%-11.3pp
Net margin-37%-10.1pp
FCF margin-17.6%-5.9pp

Returns & leverage

See full
Return on equity-33.7%-6.4pp
Debt / equity0.0×
Current ratio3.1×+0.2×

Where this comes from

Reported directly by American Well in its filing.

Tagged under the XBRL concept us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures.

The official record: American Well’s 10-K, filed February 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about American Well's equity method investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is American Well's equity method investments?
American Well (AMWL) reported equity method investments of $0 in Q4 2025.
How has American Well's equity method investments changed year-over-year?
American Well's equity method investments decreased by 100.0% year-over-year, from $1.5M to $0.
What is the long-term trend for American Well's equity method investments?
Over 4 years (2020 to 2025), American Well's equity method investments has grown at a -100.0% compound annual growth rate (CAGR), from $752K to $0.
What does equity method investments mean?
Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.